Glyphic Biotechnologies

Glyphic Biotechnologies is an early-stage innovator targeting the transformative opportunity in proteomics with its proprietary ProSE™ technology. The platform employs a three-step process of peptide functionalization, molecular expansion to space out amino acids, and nanopore-based sequencing to read single-amino-acid signatures. Positioned as a pre-revenue platform company, Glyphic is building its team and technology with a target milestone around 2026, aiming to address the critical gap between genomic information and functional protein biology for research and future diagnostic/therapeutic applications.

Protein Sequencing by Expansion (ProSE™): A three-step platform involving peptide functionalization, molecular expansion to space amino acids, and nanopore-based electrical sequencing to enable de novo, single-molecule protein sequencing with discrimination of all 20 amino acids and PTMs.

Glyphic operates in the competitive next-generation proteomics space, facing companies like Quantum-Si (single-molecule semiconductor sequencing), Nautilus Biotechnology (high-plex affinity-based proteomics), and Seer (nanoparticle-based enrichment). Its differentiation hinges on the claimed ability for true de novo, single-amino-acid sequencing of all 20 AAs and PTMs, a technical hurdle none have fully solved.